InvestorsHub Logo
Followers 55
Posts 13535
Boards Moderated 0
Alias Born 10/12/2006

Re: None

Wednesday, 04/19/2017 9:14:03 PM

Wednesday, April 19, 2017 9:14:03 PM

Post# of 2028
Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Cara Therapeutics (NASDAQ: CARA) after the company bolstered its balance sheet with $87M in net proceeds from an equity raise, which he believes will fund significant Phase III progress in uremic pruritus (UP) and postop pain into 2H19.

He also believes the Phase II CR845 uremic pruritus results are strong enough to warrant a Phase III program leading to reduced clinical and execution risk.

The two factors together make him comfortable raising the PT to $27 from $23.

https://www.streetinsider.com/Analyst+Comments/Cara+Therapeutics+%28CARA%29%3A+Equity+Raise+Reduces+Pipeline+Risk+-+Piper+Jaffray/12752616.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CARA News